Pds Biotechnology Corporation · NASDAQ:PDSB
Pds Biotechnology — Investor Presentation (June 2020)
32 slides from Pds Biotechnology's investor presentation, Jun 30, 2020
Slide 1: A new generation of multi-functional cancer immunotherapies
®) PDS Biotechnology A new generation of multi-functional cancer immunotherapies Frank Bedu-Addo Ph.D. President & CEO
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation (“PDSB”), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre-clinical and clinical drug development activi
Slide 3: PDS Biotechnology leadership team has demonstrated success in development and commercialization
PDS Biotechnology leadership team has demonstrated success in the development and commercialization of leading pharmaceutical products ®™ Frank Bedu-Addo, PhD + Senior executive experience with management of strategy and > Chief Executive Officer execution at both large pharma and biotechs Eimeria’
Slide 4: PDS Biotech is well-poised to transform vaccines and cancer treatment
PDS Biotech is well-poised to transform vaccines and cancer treatment by fulfilling the promise of immunotherapy Powerful immunotherapy platform that activates therapeutic and preventive immunological pathways y) Demonstrated potential for strong clinical efficacy and durability of response with min
Slide 5: PDS Biotech is a clinical stage biotechnology company developing immunotherapies
PDS Biotech is a clinical stage biotechnology company developing a pipeline of immunotherapies based on the proprietary Versamune® platform CORPORATE OVERVIEW VERSAMUNE® PLATFORM PIPELINE = Publicly listed on NASDAQ: = Versatile and potent T-cell- Oncology PDSB activating platform = PDS0101 (Phase 2
Slide 6: Versamune Platform
Slide 7: Versamune is a proprietary T-cell activating platform
Versamune® is a proprietary T-cell activating platform engineered to induce a robust, targeted anti-tumor response in vivo Water-insoluble Fatty acids/hydrocarbon chains Water-soluble and positively charged head-group coats the particle surface fe) 7 “ ae J in ee H cr te) R- ic of 1,2-dioleoy!-trit
Slide 8: Versamune has demonstrated the potential to overcome the challenges of immunotherapy
Versamune® has demonstrated the potential to overcome the challenges of immunotherapy in oncology and infectious disease Challenges of Immunotherapy Inability to perform the necessary steps to induce a strong therapeutic killer T-cell response in-vivo Mechanistic limitations have resulted in lack of
Slide 9: # of Antigen-Recognizing T-Cells
# of Antigen-Recognizing T-Cells Greater quantity and quality of Versamune®-induced killer T-cells may result in unique ability to eradicate HPV-positive tumors after a single dose Produces > 10-fold number of highly potent (polyfunctional) killer T-cells vs. other T-cell technologies 500 1750 4 2 g
Slide 10: Versamune and a proprietary antigen engineered for simplicity and ease of administration
The combination of Versamune® and a proprietary antigen is engineered for simplicity and ease of administration Vials of HPV16 mix (L) Versamune® formulation Delivered via and Versamune® (R) is mixed before injection* subcutaneous injection ®) PDS Biotechnology *Electron microscopy picture 10
Slide 11: Oncology
Slide 12: PDS Biotech's immuno-oncology pipeline
PDS Biotech’s immuno-oncology pipeline combines the Versamune® platform with proprietary tumor antigens across several cancer types PRODUCT INDICA’ COMBINATIO Frc |p: | pa ie PARTNER(S) Oncology PDSo101 First line treatment of recurrent / metastatic HPV16) head and neck cancer LSE r € MERCK Ne MDAnd
Slide 13: PDS0101 is designed to treat cancers caused by HPV
PDS0101 is designed to treat cancers caused by human papillomavirus (HPV) Approximately 43,000 patients are diagnosed with HPV-associated cancers each year, a number unlikely to be impacted by increased use of HPV preventive vaccines in the next decade + Oropharyngeal (head & neck) cancers Females (
Slide 14: PDS0101 Phase 1 clinical trial: high levels of HPV-specific killer T-cells
PDS0101 Phase 1 clinical trial: Unique in vivo demonstration of high levels of HPV-specific killer T-cells in circulating blood Clinical study results successfully demonstrate translation of Versamune®’s multi- functional mechanism of action between pre-clinical models and humans ium Activated Kille
Slide 15: Follow-up of patients in PDS0101 Phase 1 study showed clinical responses
Follow-up of patients in PDS0101 Phase 1 study demonstrated promising clinical responses at all three tested doses « Apost-hoc, retrospective analysis, demonstrated complete lesion regression in at least 60% of evaluable patients (6/10) as early as 1-3 months after treatment — No lesion recurrence o
Slide 16: Clinical strategy in advanced cancer: efficiency and risk mitigation
PDS Biotech clinical strategy in advanced cancer is to focus on efficiency and risk mitigation to proof of concept Versamune®-based immunotherapies are being developed as combination therapies to exploit the demonstrated synergies between Versamune® and other anti-cancer agents ¢ Checkpoint inhibito
Slide 17: T-cell response enhances checkpoint inhibitor efficacy in B16 melanoma
The robust T-cell response induced by Versamune® results in the potential for enhancement of efficacy of checkpoint inhibitors in immune suppressive B16 melanoma Early clinical studies showed the checkpoint inhibitor to be ineffective in treating B16 melanoma, a notoriously difficult model to treat.
Slide 18: PDS0101 is the only compound selected by Merck in combination with KEYTRUDA
PDS0101 is the only compound selected by Merck for evaluation in combination with KEYTRUDA¢® as first line cancer therapy * PDS0O101 + KEYTRUDA® -— Keytruda® first immunotherapy approved as standard of care for first line treatment of cancer (recurrent or metastatic head and neck cancer) - PDS0101 f
Slide 19: Phase 2 study of PDS0101 with KEYTRUDA in head and neck cancer planned
A Phase 2 study of PDS0101 in combination with KEYTRUDA® in first-line treatment of recurrent/metastatic head and neck cancer is planned * PDS Biotechnology-sponsored study with KEYTRUDA® supplied by Merck « Primary endpoints: Efficacy, safety and tolerability * Study design: Phase 2 open-label stud
Slide 20: Investigator-Led Phase 2 studies of PDS0101 in combination therapy
Investigator-Led Phase 2 studies of PDS0101 in combination therapy will evaluate efficacy and safety in treatment of advanced HPV cancers Phase 2 Open Label Study Fi ‘i Funded By (Safety and Efficacy) Important Considerations + Advanced HPV-associated * NCI selection and confirmation of Initiated in
Slide 21: Infectious Disease
Slide 22: PDS Biotech's infectious disease pipeline
PDS Biotech’s infectious disease pipeline combines the Versamune® platform with proprietary tumor antigens across several diseases PRODUCT INDICATION COMBINATION [rc |e: | re | ps |r | PARTNER(S) Infectious Disease Poa t ; _ is) Prevention of tuberculosis D Gra rma PDSo202 a 5 4 aiflisenca) Universa
Slide 23: Versamune enhances neutralizing antibodies against influenza strains
Versamune® dramatically enhances induction of neutralizing antibodies against various influenza strains and enables significant dose sparing The addition of Versamune® to Fluzone®, a seasonal influenza vaccine, resulted in a 40-fold increase in protective HAI titers — achieving superior levels of HA
Slide 24: Versamune vaccines induce antibody, helper and killer T-cell responses
Versamune®-based vaccines uniquely induce strong antibody, helper and killer T-cell responses against an antigen to provide superior protection Versamune® uniquely induces both potent antibody mediated responses and high levels of helper and killer T-cells vs. CFA when both are administered with the
Slide 25: Preclinical testing of Versamune-based COVID-19 vaccine candidates
Preclinical testing of PDS Biotech’s Versamune®-based COVID-19 vaccine candidates is ongoing with a clear target profile Induction of highly-potent, SARS-CoV-2-specific killer T-cells y) Demonstrate high levels of both SARS-CoV-2-specific T-cell and antibody response after a single dose 3. CN safety
Slide 26: COVID-19 vaccine induces rapid antibody responses in two weeks
Versamune®-based COVID-19 vaccine induces rapid and potent antibody responses to SARS-CoV-2 in two weeks Initial preclinical data suggest Versamune® induces antibodies at a level equivalent to those observed in the sickest COVID-19 patients within 2 weeks of vaccination Day 14: Neutralizing Antibody
Slide 27: COVID vaccine induces strong T-cell responses in two weeks
In addition, Versamune®-based COVID vaccine uniquely induces strong T-cell responses against SARS-CoV-2 in two weeks Initial preclinical data suggest Versamune® induces T-cells — including polyfunctional CD8+ killer T-cells - against SARS-CoV-2 when combined with either the Spike S1 protein or the f
Slide 28: &
&
Slide 29: Multiple layers of technology and product protection for Versamune
Multiple layers of technology and product protection for Versamune®- related products through mid-2030s are secured * Versamune® and associated patents are owned and licensed by PDS Biotech « Patents cover methods and compositions stimulating/promoting an immune response with Versamune® technology i
Slide 30: Strong financial position to support near-term milestones
Strong financial position to support near-term milestones Timing of the 2020 milestones will be impacted by the COVID-19 pandemic Cash™ Share Price” $2.60 Market Cap* $36.9M Debt’ —- ®) PDS Biotechnology * June 29, 2020 PDS0201 (M. tuberculosis): Complete development and feasibility testing PDS0202
Slide 31: PDS Biotech is well-poised to transform vaccines and cancer treatment
PDS Biotech is well-poised to transform vaccines and cancer treatment by fulfilling the promise of immunotherapy Powerful immunotherapy platform that activates therapeutic and preventive immunological pathways y) Demonstrated potential for strong clinical efficacy and durability of response with min
Slide 32: A new generation of multi-functional cancer immunotherapies
©) PDS Biotechnology A new generation of multi-functional cancer immunotherapies
PDS Biotechnology — Investor Presentation (June 2020) on 6ix